121 related articles for article (PubMed ID: 8695173)
1. Tumour-induced hypercalcaemia, resistant to systemic anti-hypercalcaemic and chemo-endocrine treatments, but responding to radiotherapy in a breast cancer patient.
Nesković-Konstantinović Z; Susnjar S; Vasović S; Borojević N; Mitrović L; Radosević-Jelić L; Radulović S
Acta Oncol; 1996; 35(4):501-3. PubMed ID: 8695173
[No Abstract] [Full Text] [Related]
2. Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.
Sims EC; Rogers PB; Besser GM; Plowman PN
Clin Oncol (R Coll Radiol); 1998; 10(6):407-9. PubMed ID: 9890546
[TBL] [Abstract][Full Text] [Related]
3. [Update on paraneoplastic hypercalcemia. Our experience in the treatment of hypercalcemic states of patients with advanced breast carcinoma].
Grottolo A; Ferrari V; Lazzari R; Mariano MR; Zambruni A; Zaniboni A
Minerva Med; 1988 Jul; 79(7):527-31. PubMed ID: 3405454
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of tumour-induced microangiopathic haemolytic anaemia.
Chalasani P; Segar JM; Marron M; Stopeck A
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26744538
[TBL] [Abstract][Full Text] [Related]
5. A woman with breast cancer and severe impaired lactose tolerance: an intriguing therapeutic dilemma.
Zagouri F; Dimitrakakis C; Dimopoulos MA; Tsigginou A; Antsaklis A; Papadimitriou CA
Breast J; 2012; 18(6):628-9. PubMed ID: 23009609
[No Abstract] [Full Text] [Related]
6. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
Tai N; Inoue D
Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of malignancy associated hypercalcemia].
Tai N; Inoue D
Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
[TBL] [Abstract][Full Text] [Related]
8. Unobstructed biliary tract dilatation in a patient with breast carcinoma and dermatomyositis: a new paraneoplastic manifestation?
Katsinelos P; Stavros D; Pirpilidis I; Christodoulou K; Xiarchos P; Zisis A; Nikos E
Am J Gastroenterol; 1999 Nov; 94(11):3383-5. PubMed ID: 10566763
[No Abstract] [Full Text] [Related]
9. [Medical treatment of malignant hypercalcemia].
Eto S; Nakano Y; Okada Y
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2311-8. PubMed ID: 8259844
[TBL] [Abstract][Full Text] [Related]
10. Malignancy associated hypercalcaemia-responsiveness to IV bisphosphonates and prognosis in a palliative population.
Mallik S; Mallik G; Macabulos ST; Dorigo A
Support Care Cancer; 2016 Apr; 24(4):1771-7. PubMed ID: 26441077
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
[TBL] [Abstract][Full Text] [Related]
12. Different outcome variables yield different results!
Brouckaert O; Wildiers H; Neven P
Ann Oncol; 2013 Feb; 24(2):554. PubMed ID: 23277485
[No Abstract] [Full Text] [Related]
13. Drug therapy of hypercalcemia due to malignancy.
Raue F; Pecherstorfer M
Recent Results Cancer Res; 1994; 137():138-60. PubMed ID: 7878293
[No Abstract] [Full Text] [Related]
14. [Paraneoplastic gastroparesis].
Berghmans T; Musch W; Brenez D; Malarme M
Rev Med Brux; 1993; 14(9-10):275-8. PubMed ID: 8310196
[TBL] [Abstract][Full Text] [Related]
15. Hypercalcemic complication in patients with oral squamous cell carcinoma.
Iwase M; Takemi T; Manabe M; Nagumo M
Int J Oral Maxillofac Surg; 2003 Apr; 32(2):174-80. PubMed ID: 12729778
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic possibilities in paraneoplastic hypercalcemia].
Schürer CC; Peters U; Fischer JT
Med Welt; 1981 Aug; 32(32-33):1219-21. PubMed ID: 6456397
[No Abstract] [Full Text] [Related]
17. Reply to 'Different outcome variables yield different results', by O. Brouckaert et al.
Truin W; Voogd AC; Roumen RMH
Ann Oncol; 2013 Feb; 24(2):555. PubMed ID: 23341480
[No Abstract] [Full Text] [Related]
18. Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour.
Teng J; Abell S; Hicks RJ; Hofman MS; Sachithanandan N; McKelvie P; MacIsaac RJ
Clin Endocrinol (Oxf); 2014 Dec; 81(6):940-2. PubMed ID: 24890549
[No Abstract] [Full Text] [Related]
19. [Subacute cutaneous lupus erythematosus and cancer: two cases and literature review].
Gantzer A; Regnier S; Cosnes A; Ortonne N; Wolkenstein P; Bagot M; Duong TA
Ann Dermatol Venereol; 2011 May; 138(5):409-17. PubMed ID: 21570567
[TBL] [Abstract][Full Text] [Related]
20. [Fatal hypercalcemia in tamoxifen. Chief symptom: increasing somnolence in a 68-year-old patient].
Mayer O; Hricko P; Bernhard P; Leibundgut U
Praxis (Bern 1994); 1999 Nov; 88(46):1923-4. PubMed ID: 10593148
[No Abstract] [Full Text] [Related]
[Next] [New Search]
